Stromal tumor‑infiltrating lymphocytes evaluated on H&E‑stained slides are an independent prognostic factor in epithelial ovarian cancer and ovarian serous carcinoma

Hwang,Chungsu; Lee,So  Jung; Lee,Jung  Hee; Kim,Ki  Hyung; Suh,Dong  Soo; Kwon,Byung‑Su; Choi,Kyung  Un

doi:10.3892/ol.2019.10095

Stromal tumor‑infiltrating lymphocytes evaluated on H&E‑stained slides are an independent prognostic factor in epithelial ovarian cancer and ovarian serous carcinoma

Authors:
- Chungsu Hwang
- So Jung Lee
- Jung Hee Lee
- Ki Hyung Kim
- Dong Soo Suh
- Byung‑Su Kwon
- Kyung Un Choi
View Affiliations

Affiliations: Department of Pathology, Pusan National University Yangsan Hospital, Yangsan, Gyeongsangnam-do 50612, Republic of Korea, Department of Pathology, Pusan National University Hospital, Seo‑Gu, Busan 602‑739, Republic of Korea, Department of Obstetrics and Gynecology, Pusan National University Hospital, Seo‑Gu, Busan 602‑739, Republic of Korea
Published online on: March 1, 2019 https://doi.org/10.3892/ol.2019.10095
Pages: 4557-4565
Copyright: © Hwang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Studies on tumor‑infiltrating lymphocytes (TILs) in epithelial ovarian cancer (EOC) have focused on the clinical significance of inflammatory cells of specific subtypes that are identifiable using immunohistochemistry. However, the subtypes of inflammatory cells that reportedly affect patient survival and prognosis have differed from study to study, and few studies have examined TILs using hematoxylin and eosin (H&E) staining. Therefore, the present study aimed to identify the clinical importance of general stromal TILs in EOC by using H&E staining to apply breast cancer recommendations from the International TILs Working Group 2014 on breast cancer using H&E staining. Stromal TILs in 256 EOC cases from Pusan National University Hospital and 475 cases of high‑grade serous carcinoma from The Cancer Genome Atlas dataset were assessed. Stromal TILs were evaluated using H&E‑stained slides according to the breast cancer recommendations of the International Working Group 2014, and patients were classified into low and high stromal TIL groups according to their stromal TIL values. The associations of these groups with clinicopathologic factors were assessed, and it was confirmed that group membership correlated with survival and prognosis. According to the χ2 assessment, the stromal TIL group was associated with tumor grade. Furthermore, the stromal TIL group was associated with overall survival according to Kaplan‑Meier analysis with the log‑rank test. Finally, the stromal TIL group was an independent prognostic factor according to univariate and multivariate Cox regression analyses. In cases of EOC, the evaluation of general stromal TILs on H&E‑stained slides could be used to predict prognosis.

View Figures

View References

1	Seigel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P and Cascinelli N: Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 77:1303–1310. 1996. View Article : Google Scholar : PubMed/NCBI
3	Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO and Green AR: Tumor-infiltrating CD8⁺ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 29:1949–1955. 2011. View Article : Google Scholar : PubMed/NCBI
4	Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E and Kosma VM: Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol. 182:318–324. 1997. View Article : Google Scholar : PubMed/NCBI
5	Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T, Kato K, Kurokawa T, Suzuoki M, Nakakubo Y, et al: CD8⁺ tumor-infiltrating lymphocytes together with CD4⁺ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas. 28:e26–e31. 2004. View Article : Google Scholar : PubMed/NCBI
6	Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 348:203–213. 2003. View Article : Google Scholar : PubMed/NCBI
7	Sato E, Oison SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, et al: Intraepithelial CD8⁺ tumor-infiltrating lymphocytes and a high CD8⁺/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 102:18538–18543. 2005. View Article : Google Scholar : PubMed/NCBI
8	Webb JR, Milne K, Watson P, Deleeuw RJ and Nelson BH: Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res. 20:434–444. 2014. View Article : Google Scholar : PubMed/NCBI
9	Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, et al: Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J Clin Oncol. 31:860–867. 2013. View Article : Google Scholar : PubMed/NCBI
10	Herrero-Vicent C, Guerrero A, Gavila J, Gozalbo F, Hernandez A, Sandiego S, Algarra MA, Calatrava A, Guillem-Porta V and Ruiz-Simon A: Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy. Ecancermedicalscience. 11:7592017. View Article : Google Scholar : PubMed/NCBI
11	Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, et al: The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 26:259–271. 2014. View Article : Google Scholar : PubMed/NCBI
12	Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagali D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, et al: Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Ann Oncol. 25:1544–1550. 2014. View Article : Google Scholar : PubMed/NCBI
13	Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, Pfitzner BM, Salat C, Loi S, Schmitt WD, et al: Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative breast cancers. J Clin Oncol. 33:983–991. 2015. View Article : Google Scholar : PubMed/NCBI
14	Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphener TJ, et al: Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 32:2959–2966. 2014. View Article : Google Scholar : PubMed/NCBI
15	Mignon S, Wilard-Gallo K, Van den Eynden G, Salgado R, Waelput W, Decoster L, Marien K, Vansteenkiste J, Teugels E and De Greve J: The relationship of TILs and PD-L1 expression in NSCLC adenocarcinoma in little to non-smokers with driver mutations and outcome parameters. J Thorac Oncol. 12:S13312017. View Article : Google Scholar
16	Kang BW, Seo An, Yoon S, Bae HI, Jeon SW, Kwon OK, Chung HY, Yi W, Kang H and Kim JG: Prognostic value of tumor-infiltrating lymphocytes in Epstein-Barr virus-associated gastric cancer. Ann Oncol. 27:494–501. 2016. View Article : Google Scholar : PubMed/NCBI
17	Sudo T, Nishida R, Kawahara A, Saisho K, Mimori K, Yamada A, Mizogchi A, Kadoya K, Matono S, Mori N, et al: Clinical impact of tumor-infiltrating lymphocytes in esophageal squamous cell carcinoma. Ann Surg Oncol. 24:3763–3770. 2017. View Article : Google Scholar : PubMed/NCBI
18	Ahn SG, Jeong J, Hong S and Jung WH: Current issues and clinical evidence in tumor-infiltrating lymphocytes in breast cancer. J Pathol Transl Med. 49:355–363. 2015. View Article : Google Scholar : PubMed/NCBI
19	James FR, Jiminez-Linan M, Alsop J, Mack M, Song H, Brenton JD, Pharoah PDP and Ali HR: Association between tumor infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer. BMC Cancer. 17:6572017. View Article : Google Scholar : PubMed/NCBI
20	Tomsová M, Melichar B, Sedlákovál I and Steiner I: Prognostic significance of CD3⁺ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol. 108:415–420. 2008. View Article : Google Scholar : PubMed/NCBI
21	Hermans C, Anz D, Engel J, Kirhner T, Endres S and Mayr D: Analysis of FoxP3⁺ T-regulatory cells and CD8⁺ T-cells in ovarian carcinoma: Location and tumor infiltrating patterns are key prognostic markers. PLos One. 9:e1117572014. View Article : Google Scholar : PubMed/NCBI
22	Slaney CY, Kershaw MH and Darcy PK: Trafficking of T cells into tumor. Cancer Res. 74:7168–7174. 2014. View Article : Google Scholar : PubMed/NCBI
23	Schietinger A, Arina A, Liu RB, Wells S, Huang J, Engels B, Bindokas V, Bartkowiak T, Lee D, Hermann A, et al: Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer. Oncoimmunology. 2:e266772013. View Article : Google Scholar : PubMed/NCBI